SiliconInvestor
     Advanced Search   [ sign in ]

sponsor
Sponsor

 Biotech / Medical | Biotech Valuation

Previous 10 | Next 10 
To: Biomaven who wrote (38207)4/27/2012 8:58:19 PM
From: Biomaven   of 40260
 
Stendra label is vanilla - looks like the FDA just cut and pasted the other ED drugs' labels. Nothing about onset of action, so that makes it much harder to market.

Peter

Share Recommend | Keep | Reply | Mark as Last Read

To: software salesperson who wrote (36357)4/29/2012 11:16:04 AM
From: software salesperson   of 40260
 
On this teleconference, Rudy Tanzi provides an overview on the genetics of Alzheimer's and an update on new research approaches. He then answers questions, many of which come from members of the research community.

Audio only, yet easy to follow.


usagainstalzheimers.org 

Share Recommend | Keep | Reply | Mark as Last Read

From: Pistol Pete4/30/2012 12:34:12 PM
   of 40260
 
IMUC uplisting to a major exchange coming soon. New article out today weighs in on the benefits of being traded on AMEX or NASDAQ. Its worth a read.

seekingalpha.com 

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

From: Biomaven5/1/2012 1:07:52 PM
   of 40260
 
Best of ASCO selected:

boa2012.asco.org 

Here are some abstracts with relevance to biotechs that I noted - let me know if I've missed any:

(KERX): Abstract #LBA3501: Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). (J. C. Bendell)


(EXEL) Abstract #5508: An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. (P. Schoffski)


(AVEO) Abstract #CRA4501: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. (R. J. Motzer)


(MDVN) Abstract #4519: Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. (J. S. De Bono)


(CELGZ) Abstract #CRA1002: CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). (H. S. Rugo)


(IMGN) Abstract #LBA1: Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (K. L. Blackwell)


(ARIA) Abstract #6503: PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. (J. E. Cortes)


(PCYC)Abstract #6507: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. (J. C. Byrd)




Peter

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: Biomaven who wrote (38211)5/1/2012 1:33:31 PM
From: Biomaven   of 40260
 
KERX certainly the odd-man out in that list. Maybe this was decided before the news of their trial failure reached the folks at ASCO?

Wonder if CLDX would have made this list if they hadn't checked the wrong box on their submission....

Peter

Share Recommend | Keep | Reply | Mark as Last Read

To: Biomaven who wrote (38211)5/1/2012 4:59:50 PM
From: Arthur Radley   of 40260
 
The dates reflected on your post indicates July, 2012, but isn't the annual ASCO meeting taking place June 1-5th in Chicago. What is the difference in dates? Is this a separate ASCO meeting and wouldn't these companies present at the June conference for better exposure?

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Arthur Radley who wrote (38213)5/1/2012 5:12:47 PM
From: Biomaven   of 40260
 
This is the "Best of ASCO" program where they select some of the best abstracts to be presented at ASCO and discuss them in other cities like Chicago and Boston at a later date. Sort of a mini-ASCO for folks that can't travel to the real thing.

Peter

Share Recommend | Keep | Reply | Mark as Last Read

From: Ian@SI5/1/2012 5:55:46 PM
   of 40260
 
researchnews.osu.edu 

too much betacarotene, even if solely through diet, may be harmful...

RESEARCHERS FIND POTENTIAL ‘DARK SIDE’ TO DIETS HIGH IN BETA-CAROTENE COLUMBUS, Ohio - New research suggests that there could be health hazards associated with consuming excessive amounts of beta-carotene.

...

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Pistol Pete who wrote (38210)5/1/2012 9:58:14 PM
From: Robohogs   of 40260
 
I have to say that I have not been all that impressed by the author's other biotech articles. He may be making money, but I think it is for the wrong reasons. Anyone else with thoughts?

Jon

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Ian@SI who wrote (38215)5/2/2012 1:48:30 PM
From: DewDiligence_on_SI   of 40260
 
>The compounds also have been found previously in cantaloupe and other orange-fleshed melons, suggesting humans might even absorb these molecules directly from their diet.<


Should I toss my cantaloupes? I’ve been having a generous portion almost every day.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (3)
Previous 10 | Next 10 

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.